Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belantamab mafodotin + nirogacestat
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
A combination therapy under investigation for relapsed/refractory multiple myeloma, consisting of belantamab mafodotin (an antibody-drug conjugate targeting B-cell maturation antigen (BCMA)) and nirogacestat (an oral, small molecule gamma-secretase inhibitor). Belantamab mafodotin blocks and kills BCMA-expressing myeloma cells through antibody-dependent mechanisms and delivery of a cytotoxic agent. Nirogacestat, by inhibiting gamma-secretase, increases membrane BCMA and reduces soluble BCMA, enhancing the effect of anti-BCMA therapies. This combination is being evaluated for synergistic anti-myeloma activity and reduction of high-grade ocular toxicity seen with belantamab mafodotin monotherapy. The combination is being studied primarily in patients with relapsed/refractory multiple myeloma who have had multiple prior lines of therapy[1][2][3][6].
- Other names
- belantamab mafodotin-blmfbelamaf + nirogacestat
02
Targets
BCMA (B-cell maturation antigen)GSEC (Gamma-Secretase Complex)
Beyond the preview
Go deeper on belantamab mafodotin + nirogacestat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belantamab mafodotin + nirogacestat.